Latest Conference Articles

September 10th 2022, 5:34pm

ESMO Congress

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

September 10th 2022, 5:25pm

ESMO Congress

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

September 10th 2022, 4:40pm

ESMO Congress

Neoadjuvant talimogene laherparepvec plus surgery provided sustained, durable improvements in efficacy vs surgery alone in patients with resectable stage IIIB to IVM1a melanoma.

September 10th 2022, 4:31pm

ESMO Congress

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

September 10th 2022, 3:15pm

ESMO Congress

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

September 10th 2022, 3:10pm

ESMO Congress

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

September 10th 2022, 2:55pm

ESMO Congress

A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

September 10th 2022, 2:35pm

ESMO Congress

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

September 10th 2022, 2:31pm

ESMO Congress

Nirogacestat led to a 71% reduction in the risk of disease progression or death compared with placebo in patients with progressive desmoid tumors.

September 10th 2022, 1:45pm

OncLive News Network: On Location at ESMO 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 9th 2022, 7:25pm

ESMO Congress

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

September 9th 2022, 7:05pm

ESMO Congress

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

September 9th 2022, 6:23pm

ESMO Congress

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

September 9th 2022, 5:55pm

ESMO Congress

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.

September 9th 2022, 5:32pm

ESMO Congress

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

September 9th 2022, 5:15pm

ESMO Congress

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

September 9th 2022, 4:36pm

ESMO Congress

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

September 9th 2022, 4:15pm

ESMO Congress

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

September 9th 2022, 3:10pm

ESMO Congress

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

September 9th 2022, 2:55pm

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.